Dr. Erik J. Verner Ph.D. serves as Vice President of Chemistry Research of the Company. Dr. Verner was Director of Chemistry for Principia Biopharma Inc., a biopharmaceutical company. Dr. Verner served as Director of Chemistry of Pharmacyclics, Inc., a biopharmaceutical company, from 2008 to February 2011, where he served as a principal scientist from 2006 to 2008. From 1996 to 2006, Dr. Verner was a principal scientist at Axys Pharmaceuticals, Inc. (formerly Arris Pharmaceuticals, Incorporated), a biotechnology company, and Celera Corporation, a subsidiary of Axys Pharmaceuticals, Inc. He was a senior scientist at Immunopharmaceutics, Inc., a biotechnology company, from 1993 to 1996. Dr. Verner received a B.S. in Chemistry from the University of Idaho and a Ph.D. in Organic Chemistry from the University of Pittsburgh.
Erik Verner is 53, he's been the Vice President of Chemistry Research of Corvus Pharmaceuticals Inc since 2015. There are 14 older and 3 younger executives at Corvus Pharmaceuticals Inc. The oldest executive at Corvus Pharmaceuticals Inc is Dr. Richard A. Miller M.D., 70, who is the Co-Founder, Pres, CEO & Chairman.
Erik's mailing address filed with the SEC is C/O CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME, CA, 94010.
Over the last 9 years, insiders at Corvus Pharmaceuticals Inc have traded over $52,808,904 worth of Corvus Pharmaceuticals Inc stock and bought 11,523,300 units worth $85,214,510 . The most active insiders traders include Holdings A/S Novo, Street Partners Llc Adams a Capital, Llc Eco R1. On average, Corvus Pharmaceuticals Inc executives and independent directors trade stock every 46 days with the average trade being worth of $1,530,854. The most recent stock trade was executed by William Benton Jones on 6 May 2024, trading 20,000 units of CRVS stock currently worth $34,600.
corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.
Corvus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: